Palforzia: A New Hope for Children with Peanut Allergy

Palforzia is a groundbreaking treatment for children aged 1 to 17 suffering from peanut allergy, available in powder form within capsules or sachets. Patients mix the powder with soft food for consumption. The treatment is divided into three phases: an initial clinic-based phase with increasing doses under medical observation, followed by a home-based phase with daily doses increasing every two weeks, and finally, a maintenance phase with a daily dose to sustain the medicine's effects.

Clinical trials involving over 800 children have demonstrated Palforzia's efficacy. Notably, 50% of children aged 4 to 17 and 68% of those aged 1 to 3 could tolerate 1,000 mg of peanut protein with only mild symptoms, a significant improvement over placebo groups. However, Palforzia is not without its side effects, including urticaria, cough, erythema, and abdominal pain among others. It is contraindicated in patients with severe asthma, swallowing difficulties, or recent severe allergic reactions.

The European Medicines Agency has endorsed Palforzia, recognizing its benefits surpass the risks. Patients and caregivers are provided with comprehensive information on managing the treatment and its risks, including a patient card to carry at all times. Continuous monitoring of Palforzia's use and side effects ensures patient safety remains a priority.